Cargando…

FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

BACKGROUND: The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients. METHODS: Polymorphisms were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botticelli, Andrea, Mazzuca, Federica, Borro, Marina, Mazzotti, Eva, La Torre, Marco, Bonifacino, Adriana, Ciabatta, Francesca Romana, Gentile, Giovanna, Maddalena, Chiara, Simmaco, Maurizio, Marchetti, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624668/ https://www.ncbi.nlm.nih.gov/pubmed/28983344 http://dx.doi.org/10.14740/wjon934w

Ejemplares similares

Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy
por: Mazzuca, Federica, et al.
Publicado: (2015)

Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort
por: Mazzuca, Federica, et al.
Publicado: (2016)

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer
por: Borro, Marina, et al.
Publicado: (2016)

Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?
por: Botticelli, Andrea, et al.
Publicado: (2016)

Integrated OMICS tools for personalised medicine
por: Borro, Marina, et al.
Publicado: (2015)

Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine
por: Gentile, Giovanna, et al.
Publicado: (2010)

Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine
por: Gentile, Giovanna, et al.
Publicado: (2010)

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
por: Botticelli, Andrea, et al.
Publicado: (2018)

Comprehensive Assessment of the Association between FCGRs polymorphisms and the risk of systemic lupus erythematosus: Evidence from a Meta-Analysis
por: Zhu, Xiao-Wei, et al.
Publicado: (2016)

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays
por: De Luca, Ottavia, et al.
Publicado: (2022)

Validation of a small-size pooling approach targeting hospital surveillance of SARS-CoV-2 infection
por: Petrucca, Andrea, et al.
Publicado: (2020)

Frequencies of Combined Dysfunction of Cytochromes P450 2C9, 2C19, and 2D6 in an Italian Cohort: Suggestions for a More Appropriate Medication Prescribing Process
por: Gentile, Giovanna, et al.
Publicado: (2023)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
por: Mezi, Silvia, et al.
Publicado: (2023)

Multiple Chemical Sensitivity Syndrome: A Principal Component Analysis of Symptoms
por: Del Casale, Antonio, et al.
Publicado: (2020)

Evidence-Based Considerations Exploring Relations between SARS-CoV-2 Pandemic and Air Pollution: Involvement of PM2.5-Mediated Up-Regulation of the Viral Receptor ACE-2
por: Borro, Marina, et al.
Publicado: (2020)

Individualized Drugs’ Selection by Evaluation of Drug Properties, Pharmacogenomics and Clinical Parameters: Performance of a Bioinformatic Tool Compared to a Clinically Established Counselling Process
por: Borro, Marina, et al.
Publicado: (2021)

Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial
por: Roberto, Michela, et al.
Publicado: (2020)

Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN(®) System Comprehensive Approach
por: Roberto, Michela, et al.
Publicado: (2021)

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023)

The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
por: Roberto, Michela, et al.
Publicado: (2021)

Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines
por: Mazzuca, Federica, et al.
Publicado: (2018)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Dopamine DRD2 and DRD3 Polymorphisms Involvement in Nicotine Dependence in Patients with Treatment-Resistant Mental Disorders
por: del Casale, Antonio, et al.
Publicado: (2022)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study
por: Mazzuca, Federica, et al.
Publicado: (2019)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression
por: Roberto, Michela, et al.
Publicado: (2017)

Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study
por: Del Casale, Antonio, et al.
Publicado: (2022)

Optimising migraine treatment: from drug-drug interactions to personalized medicine
por: Pomes, Leda Marina, et al.
Publicado: (2019)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Electrochemotherapy as Promising Treatment Option in Rare Recurrent Cutaneous Neoplasm of the Scalp: Case Report of an Elderly Patient
por: Crimini, Edoardo, et al.
Publicado: (2019)

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
por: Botticelli, Andrea, et al.
Publicado: (2017)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sh71hlb3sqiv6ijce636vtajmj